GADOTERATE MEGLUMINE Drug Patent Profile
✉ Email this page to a colleague
When do Gadoterate Meglumine patents expire, and what generic alternatives are available?
Gadoterate Meglumine is a drug marketed by Hengrui Pharma and is included in one NDA.
The generic ingredient in GADOTERATE MEGLUMINE is gadoterate meglumine. Three suppliers are listed for this compound. Additional details are available on the gadoterate meglumine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Gadoterate Meglumine
A generic version of GADOTERATE MEGLUMINE was approved as gadoterate meglumine by HENGRUI PHARMA on April 11th, 2022.
Summary for GADOTERATE MEGLUMINE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 12 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | GADOTERATE MEGLUMINE at DailyMed |
Recent Clinical Trials for GADOTERATE MEGLUMINE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Massachusetts General Hospital | Phase 2 |
| Boehringer Ingelheim | Phase 2 |
| Bayer AG (Sponsor) | Phase 4 |
Pharmacology for GADOTERATE MEGLUMINE
| Drug Class | Gadolinium-based Contrast Agent |
| Mechanism of Action | Magnetic Resonance Contrast Activity |
US Patents and Regulatory Information for GADOTERATE MEGLUMINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hengrui Pharma | GADOTERATE MEGLUMINE | gadoterate meglumine | SOLUTION;INTRAVENOUS | 215304-001 | Apr 11, 2022 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Hengrui Pharma | GADOTERATE MEGLUMINE | gadoterate meglumine | SOLUTION;INTRAVENOUS | 215304-004 | Apr 11, 2022 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Hengrui Pharma | GADOTERATE MEGLUMINE | gadoterate meglumine | SOLUTION;INTRAVENOUS | 215304-002 | Apr 11, 2022 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Hengrui Pharma | GADOTERATE MEGLUMINE | gadoterate meglumine | SOLUTION;INTRAVENOUS | 215304-003 | Apr 11, 2022 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Hengrui Pharma | GADOTERATE MEGLUMINE | gadoterate meglumine | SOLUTION;INTRAVENOUS | 215304-005 | Apr 15, 2022 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
